Regencell

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Company Profile and Mission Regencell Bioscience is an early-stage biotech company focused on Traditional Chinese Medicine. Headquartered in Causeway Bay, Hong Kong, Regencell researches, develops, and aims to commercialize herbal treatment formulae for neurocognitive disorders – primarily Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD) marketbeat.com insidermonkey.com. The company’s approach is based on the “Sik-Kee Au TCM Brain Theory,” a proprietary herbal methodology developed by the CEO’s father ts2.tech. Founded in 2014 by CEO Yat-Gai Au, Regencell went public on NASDAQ in July 2021 stockanalysis.com. The firm positions itself as a socially responsible, mission-driven enterprise: “Our goal is to save and improve the lives of

7 October 2025

Regencell (RGC) Stock Skyrockets 64,000% – Miracle Biotech or Bubble?

RGC’s 2025 Rollercoaster: From Penny Stock to $33B Phenomenon Regencell Bioscience’s journey in 2025 has been nothing short of astonishing. The company went from an obscure penny stock (literally trading under 10 cents) to a meteoric high of $83.60 within months stockanalysis.com. This 820-fold increase was “far stranger” than a typical biotech breakthrough – it happened without any major scientific news or product launch gurufocus.com. Instead, a perfect storm of speculative forces sent RGC into the stratosphere. The catalyst was announced in early June: a 38-for-1 stock split. Overnight, Regencell’s share count multiplied and the price per share dropped from

4 October 2025

Biotech · Financial News · Investing · Market Analysis · NASDAQ:RGC · Stock Market

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder marketbeat.com. It has even explored herbal COVID-19 remedies in the past, though these remain experimental stocktitan.net. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding (largely from its founder) and IPO proceeds. In the

25 September 2025

Biotech News · Company Analysis · Financial Trends · Investing · Stock Market